In the external validation, the same-variant and significant-variant strategies were used to further verify seven plasma proteins identified in the primary analysis, demonstrating that CPB2, GSTM3, NTNG1, and FAM171B also had significant associations with the risk of SCLC (Figure 2). The gene discussed is NTNG1; the disease is small cell lung carcinoma.